semaglutide mash fda approval 🎉Exciting news that is now approved for (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% GLP-1 BREAKTHROUGH: FDA APPROVES TREATMENT

Hypertension has been increasingly recognized as a potential risk factor for reduced bone mineral density and osteoporotic fractures, potentially through shared pathophysiological pathways such as chronic inflammation, oxidative stress, and impaired calcium metabolism

Treatment drugs target rapidly dividing cells, but the inflammatory cascade simultaneously damages healthy mitochondria responsible for ATP energy production (PMC)

Measurement of circulating bacterial products such as lipopolysaccharide (LPS) or bacterial DNA shows bacterial translocation across a compromised barrier

Infection control practices (safe injection and medication vial practices)

How a drug for diabetes and obesity may help heal the liver The director of VCUs liver institute says a substance found in medications like Wegovy and Ozempic can address not only metabolic issues facing patients with liver disease but the liver disease itself